Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives $44.50 Average Price Target from Brokerages

Maze Therapeutics, Inc. (NASDAQ:MAZE) has been assigned a consensus recommendation of “Buy” from the eleven research firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $44.50.

MAZE has been the topic of a number of recent research reports. BTIG Research raised their price objective on shares of Maze Therapeutics from $37.00 to $46.00 and gave the company a “buy” rating in a research note on Friday, January 16th. HC Wainwright reaffirmed a “buy” rating on shares of Maze Therapeutics in a research report on Wednesday. Guggenheim reiterated a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research note on Friday, December 19th. Lifesci Capital raised Maze Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a report on Thursday, January 22nd.

Insider Buying and Selling at Maze Therapeutics

In other Maze Therapeutics news, CMO Harold Bernstein sold 45,000 shares of Maze Therapeutics stock in a transaction on Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $1,825,200.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Amy Bachrodt sold 10,000 shares of the company’s stock in a transaction on Monday, December 29th. The stock was sold at an average price of $40.58, for a total transaction of $405,800.00. Following the completion of the sale, the senior vice president owned 12,965 shares of the company’s stock, valued at approximately $526,119.70. The trade was a 43.54% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 172,500 shares of company stock worth $7,002,267.

Hedge Funds Weigh In On Maze Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. CWM LLC bought a new stake in Maze Therapeutics during the second quarter worth $28,000. GF Fund Management CO. LTD. purchased a new stake in shares of Maze Therapeutics during the 4th quarter valued at $39,000. Ameritas Investment Partners Inc. raised its stake in shares of Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares during the period. Russell Investments Group Ltd. raised its stake in shares of Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after purchasing an additional 1,725 shares during the period. Finally, China Universal Asset Management Co. Ltd. purchased a new position in shares of Maze Therapeutics in the 3rd quarter worth about $52,000.

Maze Therapeutics Stock Performance

Shares of Maze Therapeutics stock opened at $43.58 on Friday. The stock has a market capitalization of $2.10 billion and a PE ratio of -2.09. Maze Therapeutics has a 52 week low of $6.71 and a 52 week high of $47.36. The stock has a 50 day moving average price of $40.85 and a two-hundred day moving average price of $28.98.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.